Effect of &ohgr;-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial

Study answer

What this study found

Omega-3 PUFA supplementation did not reduce transition to psychosis or improve overall symptoms and functioning when added to cognitive behavioral case management. The 6-month transition rate was 6.7% in the omega-3 group versus 5.1% in control, and the 12-month transition rate was 11.5% versus 11.2%; the hazard ratio was 1.1 (95% CI, 0.55-2.23; P = .76). Secondary outcomes were also largely null, with no significant differences at month 12 and a month 6 Global Functioning: Social and Role result favoring placebo (P = .02). These findings do not support benefit of omega-3 PUFAs under these…

Study & population

This was a multicenter randomized clinical trial conducted at 10 early psychosis services in Australia, Asia, and Europe.

Intervention

The active intervention was oral omega-3 polyunsaturated fatty acids, delivered as 4 gelatin capsules daily for 6 months.

Key limitation

Adherence was low in both groups, with 43.1% in the omega-3 arm and 41.1% in placebo classified as adherent.

View full study detailsView sourceOpen PDF

Original abstract